Elanco Animal Health Incorporated with ticker code (ELAN) have now 7 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The range between the high target price and low target price is between 19 and 8.5 calculating the average target price we see $13.21. Now with the previous closing price of $8.90 and the analysts are correct then we can expect a percentage increase in value of 48.4%. It’s also worth noting that there is a 50 day moving average of $9.18 while the 200 day moving average is $12.31. The total market capitalization for the company now stands at 4.25B. The current share price for the company is: 8.62 USD
The potential market cap would be $6,301,883,922 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 9.08 and a 1.7% return on assets.
Elanco Animal Health Incorporated is an animal health company. The Company is focused in delivering products and services to prevent and treat disease in farm animals and pets. Its portfolio serves animals across its core species consisting of dogs, cats and cattle, poultry, swine, sheep and aqua. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its parasiticide portfolios in the pet health sector include species and formulations, with products that protect pets from worms, fleas and ticks. Its over-the-counter treatments include Seresto, Advantage, Advantix, Advocate, Credelio, Interceptor Plus and Trifexis. Its Farm Animal portfolio consists of products designed to prevent, control and treat health challenges primarily focused on cattle. Its products include medicated feed additives, antibiotics, vaccines, such as Rumensin and Baytril. Its poultry products are Maxiban and others.
